Phaseline

Companies › PAQ Therapeutics

PAQ Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PT0253
KRAS G12D inhibitor
KRASPhase 1Solid TumorDec 2026
PT0511
KRAS inhibitor
KRASPhase 1Colorectal CancerOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06797336PT0253Phase 1Solid TumorOncologyDec 2026
NCT07300150PT0511Phase 1Colorectal CancerOncologyOct 2028

Targets

KRAS (2)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.